{"id":"NCT04994535","sponsor":"AbbVie","briefTitle":"A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence","officialTitle":"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOXÂ® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-08-10","primaryCompletion":"2023-06-14","completion":"2023-06-14","firstPosted":"2021-08-06","resultsPosted":"2024-08-20","lastUpdate":"2024-08-20"},"enrollment":426,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Platysma Prominence"],"interventions":[{"type":"DRUG","name":"OnabotulinumtoxinA","otherNames":["BOTOX"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"BOTOX","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence.\n\nStudy doctors will randomize participants into 1 of the 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 400 participants will be enrolled in the study across approximately 35 sites in USA, Belgium, Canada, Germany and the UK.\n\nParticipants will receive a single treatment of intramuscular injection of onabotulinumtoxinA (BOTOX) or placebo on Day 1 during this 4 month long study.\n\nParticipants will attend regular monthly visits during the study at the study site.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"Enrollment to Day 120","effectByArm":[{"arm":"Placebo","deltaMin":43,"sd":null},{"arm":"BOTOX","deltaMin":34,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":34,"countries":["United States","Belgium","Canada","Germany","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.abbvieclinicaltrials.com/study/?id=M21-310"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":216},"commonTop":["COVID-19"]}}